1. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia. 1993. 13:151–165.
Article
2. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000. 60:1259–1287.
3. Brown AM, Parsons AA, Raval P, Porter R, Tilford NS, Gager TL, et al. SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors. Br J Pharmacol. 1996. 119:110P.
4. Goldstein J, Keywood C. 251/96/14 Study Group. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache. 2002. 42:41–48.
Article
5. Kang L, Lee ST, Im W, Kim SC, Hun KS, Kim BK, et al. Screening of the A11084G polymorphism and scanning of a mitochondrial genome SNP in Korean migraineurs. J Clin Neurol. 2007. 3:127–132.
Article
6. Sakai F, Iwata M, Tashiro K, Itoyama Y, Tsuji S, Fukuuchi Y, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. Cephalalgia. 2002. 22:376–383.
Article
7. Sakai F, Diener HC, Ryan R, Poole P. Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials. Curr Med Res Opin. 2004. 20:269–277.
Article
8. Shimazawa R, Ando Y, Hidaka S, Saito K, Toyoshima S, Kobayashi F. Development of triptans in Japan: bridging strategy based on the ICH-E5 guideline. J Health Sci. 2006. 52:443–449.
Article
9. Yates RA, Tateno M, Nairn K, Ikegami A, Dane A, Kemp J. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2002. 58:247–252.
Article
10. Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002. 42:Suppl 2. S74–S83.
Article
11. Ryan R, Géraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002. 42:Suppl 2. S84–S92.
Article
12. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004. 63:261–269.
Article
13. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004. 24:Suppl 1. 1–160.
14. Protocol No. 251/96/07 Clinical Study Report. 2002. Vernalis.
15. Lee SB, Kim YI, Choi YB, Chung SW, Yang DW, Lee KS, et al. Double-blind placebo-controlled randomized clinical trial of zolmitriptan in acute treatment of migraine. J Korean Neurol Assoc. 2001. 19:29–35.
16. Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, et al. Naratriptan S2WB2004 Study Group. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Clin Ther. 2000. 22:970–980.
Article
17. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001. 358:1668–1675.
Article
18. Jo KD, Lee MC. Oral sumatriptan for acute treatment of migraine A single-blind placebo-controlled study. J Korean Neurol Assoc. 1995. 13:77–83.
19. Noh YW, Lee TG, Park KH, Kim SM, Chung KC. A double-blinded, placebo-controlled, multicenter cross-over study of 2.5mg naratriptan in acute migraineurs. Korean J Headache. 2001. 2:53–60.
20. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998. 38:184–190.
Article
21. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB, et al. The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C 90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997. 49:1210–1218.
Article
22. Dahlöf C. Safety and tolerability of the novel 5-HT 1B/1D agonist rizatriptan in migraineurs. Headache. 1999. 39:Suppl 1. S16–S18.
Article
23. Wang SJ, Fuh JL, Wu ZA. Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc. 2007. 70:39–46.
Article